{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.850","value":"29.71"},{"groupId":"OG001","spread":"23.072","value":"30.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Disease Symptoms: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.752","value":"-2.35"},{"groupId":"OG001","spread":"21.372","value":"-2.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"title":"Disease Symptoms: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG000","spread":"NA","value":"1.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Disease Symptoms: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.289","value":"17.23"},{"groupId":"OG001","spread":"14.682","value":"17.97"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Side Effects of Treatment: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.435","value":"4.52"},{"groupId":"OG001","spread":"13.955","value":"4.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"title":"Side Effects of Treatment: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"37.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Side Effects of Treatment: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.259","value":"78.00"},{"groupId":"OG001","spread":"27.233","value":"79.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Body Image: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.102","value":"-0.27"},{"groupId":"OG001","spread":"29.368","value":"-5.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"245"},{"groupId":"OG001","value":"254"}],"units":"Participants"}],"title":"Body Image: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"-33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Body Image: Last Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.170","value":"56.99"},{"groupId":"OG001","spread":"25.064","value":"60.26"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"353"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"title":"Future Perspective: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.90","value":"2.76"},{"groupId":"OG001","spread":"22.842","value":"-2.75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"248"},{"groupId":"OG001","value":"255"}],"units":"Participants"}],"title":"Future Perspective: EOT"},{"categories":[{"measurements":[{"comment":"The SD was not estimable due to single participant with event.","groupId":"OG001","spread":"NA","value":"-11.11"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Future Perspective: Last Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"354"},{"groupId":"OG001","value":"359"}],"units":"Participants"}],"description":"The EORTC-QLQ-MY-20 is a patient-completed, 20-question quality of life questionnaire that has 4 independent subscales, 2 functional subscales (body image, future perspective), and 2 symptoms scales (disease symptoms and side-effects of treatment). The participant answers questions about their health during the past week using a 4-point scale where 1=Not at All to 4=Very Much. A negative change from Baseline indicates improvement. Scores are linearly transformed to a 0-100 scale. Higher scores on the symptom scales (e.g. Disease Symptoms, Side Effects of Treatment) represent higher levels of symptomatology or problems. High scores for Body Image and Future Perspective represent better quality of life or functioning.","dispersionType":"Standard Deviation","groups":[{"description":"Ixazomib 4 mg, capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first up to EOT (up to approximately 42.9 months).","id":"OG000","title":"Ixazomib+ Lenalidomide + Dexamethasone"},{"description":"Ixazomib placebo-matching capsules, orally, once, on Days 1, 8 and 15; plus lenalidomide 25 mg, orally, once, on Days 1 through 21; and dexamethasone 40 mg, orally, once, on Days 1, 8, 15 and 22 of a 28-day cycle for multiple cycles until PD or unacceptable toxicity, whichever occurred first (up to approximately 41 months).","id":"OG001","title":"Placebo + Lenalidomide + Dexamethasone"}],"paramType":"MEAN","populationDescription":"ITT population included all randomized participants. Overall number analyzed is the number of participants available for analysis. Number analyzed is the number of participants available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, EOT and follow-up (up to approximately 97 months)","title":"Change From Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Multiple Myeloma Module (QLQ-MY-20)","type":"SECONDARY","unitOfMeasure":"score on a scale"}